{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:39Z","timestamp":1794047499289,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.287215","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T05:14:41Z","timestamp":1744262081000},"page":"2498-2502","source":"Crossref","is-referenced-by-count":4,"title":["Teclistamab &lt;i&gt;versus&lt;\/i&gt; B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis"],"prefix":"10.3324","volume":"110","author":[{"given":"Junmin","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Han","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stepan","family":"Esagian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yu","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansh K.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"80606","doi-asserted-by":"crossref","unstructured":"Mateos MV, Weisel K, De Stefano V. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022; 36(5):1371-1376.","DOI":"10.1038\/s41375-022-01531-2"},{"key":"80607","unstructured":"Afrough A, Abraham PR, Turer L. Toxicity of CAR T-cell therapy for multiple myeloma. Acta Haematol. 2025; 148(3):300-314."},{"key":"80608","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023; 388(11):1002-1014.","DOI":"10.1056\/NEJMoa2213614"},{"key":"80609","doi-asserted-by":"crossref","unstructured":"San-Miguel J, Dhakal B, Yong K. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023; 389(4):335-347.","DOI":"10.1056\/NEJMoa2303379"},{"key":"80610","doi-asserted-by":"crossref","unstructured":"Moreau P, Garfall AL, van de Donk N. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022; 387(6):495-505.","DOI":"10.1056\/NEJMoa2203478"},{"key":"80611","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023; 29(9):2259-2267.","DOI":"10.1038\/s41591-023-02528-9"},{"key":"80612","doi-asserted-by":"crossref","unstructured":"Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022; 53:101619.","DOI":"10.1016\/j.eclinm.2022.101619"},{"key":"80613","doi-asserted-by":"crossref","unstructured":"Palchuk MB, London JW, Perez-Rey D. A global federated real-world data and analytics platform for research. JAMIA Open. 2023; 6(2):ooad035.","DOI":"10.1093\/jamiaopen\/ooad035"},{"key":"80614","doi-asserted-by":"crossref","unstructured":"Andrade C. How to use percentiles to better understand standardized mean difference (SMD) as a measure of effect size. J Clin Psychiatry. 2023; 84(4):23f15028.","DOI":"10.4088\/JCP.23f15028"},{"key":"80615","doi-asserted-by":"crossref","unstructured":"Liang X, Wang Y, Luo B. Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. J Immunother Cancer. 2024; 12(11):e010064.","DOI":"10.1136\/jitc-2024-010064"},{"key":"80616","doi-asserted-by":"crossref","unstructured":"Ailawadhi S, Arnulf B, Patel KK. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024; 144(23):2389-2401.","DOI":"10.1182\/blood.2024024582"},{"key":"80617","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398(10297):314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"80618","doi-asserted-by":"crossref","unstructured":"Nath K, Shekarkhand T, Nemirovsky D. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024; 14(1):88.","DOI":"10.1038\/s41408-024-01043-5"},{"key":"80619","doi-asserted-by":"crossref","unstructured":"Rees MJ, Mammadzadeh A, Bolarinwa A. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024; 14(1):122.","DOI":"10.1038\/s41408-024-01081-z"},{"key":"80620","doi-asserted-by":"crossref","unstructured":"Mohty M, Facon T, Malard F, Harousseau JL. A roadmap towards improving outcomes in multiple myeloma. Blood Cancer J. 2024; 14(1):135.","DOI":"10.1038\/s41408-024-01115-6"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12022\/78283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12022\/78889","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12022\/78283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:33Z","timestamp":1794046113000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.287215","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}